![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
State University of New York - Upstate Medical University |
---|---|
Information provided by: | State University of New York - Upstate Medical University |
ClinicalTrials.gov Identifier: | NCT00639171 |
Magnetic Resonance Spectroscopy (MRS) is a novel imaging technique for noninvasive probing of biochemical properties of tissue. While MRS does not generate images of tumor per se it allows biochemical spectroscopic data to be obtained in vivo from user defined region-of-interest. In this manner, biochemical information elucidated by MRS can be interpreted in relation to detailed anatomy and images of metabolite distribution can be created. The aim of MRS is to identify presence and concentration of metabolites characteristic for normal and abnormal (tumor) cellular activities hence allow differential normal tissue from pathological tissue, as well as allow differentiating malignant from benign tumors.
Condition |
---|
Breast Tumors |
Study Type: | Observational |
Study Design: | Case-Only, Prospective |
Official Title: | Clinical Implementation and Evaluation of MR Spectroscopy for Breast Cancer Detection |
Estimated Enrollment: | 30 |
Study Start Date: | November 2003 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
1
Subjects with suspicious breast lesions that warrant further evaluation
|
2
Normal subjects used to evaluate software and to develop and optimize MR sequences
|
Recent in vivo studies have reported successful use of 1H and 31P MRS in differentiating between benign and malignant tumors in breast tissue. These studies demonstrated an increase in the choline metabolite peak that reflects an increase in choline-containing metabolites in 70-80% of breast carcinomas, as compared to 14-18% of benign breast tumors.The objectives would be to determine sensitivity/specificity of MRS in the context of breast CA, We will use normal volunteers to test software and to develop and optimize MR scan sequences prior to or during the testing of target subjects with suspicious breast lesion.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Subjects will be recruited from two ongoing clinical studies of the breast at SUNY Upstate Medical University.
Inclusion Criteria:
Exclusion Criteria:
Contact: Andrzej Krol, PhD | 315-464-7064 | krola@upstate.edu |
Contact: Susan Hemingway, CCRP | 315-464-5099 | hemingws@upstate.edu |
United States, New York | |
SUNY Upstate Medical University | Recruiting |
Syracuse, New York, United States, 13210 | |
Contact: Susan Hemingway, CCRP 315-464-5099 hemingws@upstate.edu |
Principal Investigator: | Andrzej Krol, PhD | State University of New York - Upstate Medical University |
Responsible Party: | SUNY Upstate Medical University ( Andrzej Krol, PhD ) |
Study ID Numbers: | SUNYUMU 4909 |
Study First Received: | March 12, 2008 |
Last Updated: | November 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00639171 History of Changes |
Health Authority: | United States: Institutional Review Board |
breast diagnostic radiology suspicious breast tumors MRI |
Skin Diseases Breast Neoplasms Breast Diseases |
Neoplasms Neoplasms by Site Skin Diseases Breast Neoplasms Breast Diseases |